03 August 2023
03 August 2023
Biogen's $7.3bn acquisition of Reata gives the company access to the only approved drug for Friedreich's Ataxia.
No statistically difference between the two arms in the overall patient population was observed.
HaemaLogiX plans to initiate the upcoming Australian trial in early 2024, possibly expanding into Europe and the US.
Topline results from the Phase II trial investigating CYB003 are expected in Q3/Q4 2023.
Establishing the drug's efficacy and reducing agitation in Alzheimer’s dementia patients are the goals of the study.
Dosing has started in the US and the first cohort in Spain has received a second dose in Theriva’s VIRAGE pancreatic cancer trial.
Phase I of the single-ascending-dose study of INI-2004 will be carried out in Australia.
The trial’s primary endpoints include improvement in central subfield thickness and visual acuity as evaluated after 12 weeks.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
